Jefferies has reaffirmed its 'buy' rating on AstraZeneca, highlighting the upcoming late-stage trial results for its heart drug eplontersen (Wainua) as a major catalyst. The CARDIO-TTRansform phase III study targets transthyretin amyloidosis, with data expected in the second half of 2026. A positive outcome could unlock around $5 billion in future sales and boost AstraZeneca's valuation. Jefferies also notes AstraZeneca's broader pipeline and forecasts steady growth driven by innovative therapies in an underdiagnosed market.
More than 20 pharmaceutical companies are actively researching and developing over 25 drugs for acute kidney injury (AKI), a condition causing sudden kidney function decline. Key players like AstraZeneca and Akebia Therapeutics are advancing therapie...
The iShares Core MSCI EAFE ETF has gained about 10.5% year to date and 24% over the past year, benefiting from a weaker U.S. dollar and strong holdings in European and Japanese megacaps like ASML and major pharma companies. The fund's performance is ...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
The FTSE 100 rose modestly by 21 points to 10,459, supported by consumer defensive stocks like Bunzl and AstraZeneca, despite heavy losses in miners and tech funds. US and Asian tech stocks, including AI and semiconductor firms, sold off sharply, wit...
The cutaneous lupus erythematosus (CLE) market is projected to expand at an 8% compound annual growth rate through 2036, driven by increased disease awareness, better diagnostics, and a focus on autoimmune disorders. New targeted therapies and biolog...
